Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "Professor"

News & Events

Global push to eliminate confusion on lung function tests

A global research network has taken another step towards standardising the way doctors interpret commonly used lung function tests.

News & Events

Early diagnosis for kids with autism

Focussing attention on a child’s first year of life is proving to be a major breakthrough in autism research.

News & Events

New clues into language development

A world-first study from The Kids for Child Health Research has identified risk factors for receptive language development in Australian children.

Research

Comparing and combining the effects of low dose ultraviolet and physical activity

Shelley Prue Gorman Hart BSc (Hons) PhD BSc (Hons) MSc PhD Honorary Research Associate Honorary Research Fellow shelley.gorman@thekids.org.au

Research

UVB phototherapy for participants with an early form of multiple sclerosis

Matt Prue Stephanie Cooper Hart Trend BCA Marketing, BSc Statistics and Applied Statistics, PhD BSc (Hons) MSc PhD BSc PhD Manager, Biostatistics

News & Events

Research to explore promising new RSV treatment supported by innovation seed funding

Researchers from the Wal-yan Respiratory Research Centre are collaborating with Virex Pharma to undertake vital research into a potential breakthrough treatment for RSV infections in young children, thanks to a $499,241 grant awarded by the WA Department of Health Innovation Seed Fund.

Research

Spatiotemporal patterns of influenza in Western Australia

Understanding the geospatial distribution of influenza infection and the risk factors associated with infection clustering can inform targeted preventive interventions. We conducted a geospatial analysis to investigate the spatial patterns and identify drivers of medically attended influenza infection across all age groups in Western Australia.

Research

The long-term effects of breastfeeding on child and adolescent mental health: A Pregnancy Cohort Study followed for 14 years

To determine whether there was an independent effect of breastfeeding on child and adolescent mental health

Research

Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1–9 years: two phase 2 randomised, controlled, observer-blinded studies

The meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) is licensed for use in children aged 10 years or older for protection against invasive serogroup B meningococcal disease. Because young children are at increased risk of invasive meningococcal disease, MenB-FHbp clinical data in this population are needed.